Evidence map›Paper›PMID 26020638›Full record

ArticlePloS one2015

Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain.

Dimitrios E Kouzoukas, Katherine L Meyer-Siegler, Fei Ma, Karin N Westlund, David E Hunt, Pedro L Vera

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Dimitrios E KouzoukasResearch and Development, Lexington Veterans Affairs Medical Center, Lexington, Kentucky, United States of America; Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, United States of America.
Katherine L Meyer-SieglerDepartment of Natural Sciences, St. Petersburg College, St. Petersburg, Florida, United States of America.
Fei MaResearch and Development, Lexington Veterans Affairs Medical Center, Lexington, Kentucky, United States of America; Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America.
Karin N WestlundResearch and Development, Lexington Veterans Affairs Medical Center, Lexington, Kentucky, United States of America; Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America.
David E HuntResearch and Development, Lexington Veterans Affairs Medical Center, Lexington, Kentucky, United States of America.
Pedro L VeraResearch and Development, Lexington Veterans Affairs Medical Center, Lexington, Kentucky, United States of America; Department of Physiology, University of Kentucky, Lexington, Kentucky, United States of America; Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America.
Lexington VA Health Care System · USUniversity of Kentucky · USSt. Petersburg College · US

Funding

MIF: a pro-inflammatory cytokine as a novel target to reduce bladder inflammationR01DK093496 · NIDDK · LEXINGTON BIOMEDICAL RESEARCH INSTITUTE · PI VERA, PEDRO L · 2012 to 2016
$1.2M
NIDDK NIH HHS DK0093496NIDDK NIH HHS R01 DK093496
6 · The paper itself

Abstract

introductionMacrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine, is constitutively expressed in urothelial cells that also express protease-activated receptors (PAR). Urothelial PAR1 receptors were shown to mediate bladder inflammation. We showed that PAR1 and PAR4 activator, thrombin, also mediates urothelial MIF release. We hypothesized that stimulation of urothelial PAR1 or PAR4 receptors elicits release of urothelial MIF that acts on MIF receptors in the urothelium to mediate bladder inflammation and pain. Thus, we examined the effect of activation of specific bladder PAR receptors on MIF release, bladder pain, micturition and histological changes.

methodsMIF release was measured in vitro after exposing immortalized human urothelial cells (UROtsa) to PAR1 or PAR4 activating peptides (AP). Female C57BL/6 mice received intravesical PAR1- or PAR4-AP for one hour to determine: 1) bladder MIF release in vivo within one hour; 2) abdominal hypersensitivity (allodynia) to von Frey filament stimulation 24 hours after treatment; 3) micturition parameters 24 hours after treatment; 4) histological changes in the bladder as a result of treatment; 5) changes in expression of bladder MIF and MIF receptors using real-time RT-PCR; 6) changes in urothelial MIF and MIF receptor, CXCR4, protein levels using quantitative immunofluorescence; 7) effect of MIF or CXCR4 antagonism.

resultsPAR1- or PAR4-AP triggered MIF release from both human urothelial cells in vitro and mouse urothelium in vivo. Twenty-four hours after intravesical PAR1- or PAR4-AP, we observed abdominal hypersensitivity in mice without changes in micturition or bladder histology. PAR4-AP was more effective and also increased expression of bladder MIF and urothelium MIF receptor, CXCR4. Bladder CXCR4 localized to the urothelium. Antagonizing MIF with ISO-1 eliminated PAR4- and reduced PAR1-induced hypersensitivity, while antagonizing CXCR4 with AMD3100 only partially prevented PAR4-induced hypersensitivity.

conclusionsBladder PAR activation elicits urothelial MIF release and urothelial MIF receptor signaling at least partly through CXCR4 to result in abdominal hypersensitivity without overt bladder inflammation. PAR-induced bladder pain may represent an interesting pre-clinical model of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) where pain occurs without apparent bladder injury or pathology. MIF is potentially a novel therapeutic target for bladder pain in IC/PBS patients.

Indexed as

AnimalsCell Line, TransformedFemaleHumansInflammationIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMicePainReceptor, PAR-1Receptors, CXCR4Receptors, ImmunologicReceptors, ThrombinUrinary BladderUrotheliumCXCR4 protein, humanCXCR4 protein, mouseIntramolecular Oxidoreductasesmacrophage migration inhibitory factor receptorMacrophage Migration-Inhibitory FactorsMIF protein, humanMif protein, mouseprotease-activated receptor 4Receptor, PAR-1Receptors, CXCR4Receptors, ImmunologicReceptors, Thrombin

Identifiers

PMID26020638
PMCPMC4447427
OpenAlexW1501260171

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.